With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
A day after Lilly’s strong clinical showing in obesity, Novo comes out swinging.
Tirzepatide is coming for Wegovy’s crown – and maybe faster than expected.
The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?
Roche awaits Tigit and Serd data, Lilly takes on obesity, and Glaxo and Pfizer race in RSV.